Please login to the form below

Not currently logged in

UK biotech funding falls 40% between 2018 and 2019

Drop attributed to global uncertainty and Neil Woodford scandal

UK Biotech

After a record-breaking year for UK biotech in 2018, the UK BioIndustry Association has revealed overall investment fell to £1.3bn in 2019 – but maintains the sector is still strongly positioned. 

Out of that amount, £679m was raised in venture capital, £64m was raised in Initial Public Offerings (IPOs) and £596m in all other public financings.

Despite the sector raising over £1bn plus of investment over the last five years, the amount raised last year is a steep drop from the £2.2bn raised in 2018.

According to Dan Mahony, partner at Polar Capital, “investor appetite for small companies has evaporated given the uncertainty surrounding Brexit”, and “the well-publicised issues with the Woodford Funds have also had an impact on sentiment”.

Despite funding falling down in the UK in 2019, the BIA noted that this drop in biotech investment was replicated in most regions across the globe.

According to the report, global venture capital deals totalled £14.5bn in 2019, down 12%, with almost all regions experiencing a decline.

Although the US continues to attract most of the global investment for biotech, it also saw a drop of 15% from last year.

The amount of venture capital raised in Europe remained the same at £2.6bn – while the UK remains the leading cluster, making up for 26% of that investment, it saw a reduction compared to 2018 when it attracted 40% of the total.

China also remained the same as 2018 with £2bn raised in venture capital, although the BIA reported this is most likely an underestimate given the rapidly evolving biotech sector in the country.

“The UK biotech sector continues to chart an ambitious global path. With five consecutive years of raising over £1bn and a 400% increase in investments since 2012, the sector is in a very strong position heading into a new decade,” said Steve Bates, chief executive of the BIA.

“However, while we welcome overseas investment, diversifying the domestic life sciences investor base is critical to capturing the full benefits of this key sector of the UK economy.

“Government efforts to leverage new scale-up capital through the British Business Bank and the UK pension funds industry should be stepped up, as should grant funding for early-stage companies through the Biomedical Catalyst,” he added.

Article by
Lucy Parsons

23rd January 2020

From: Sales



PMEA Awards 2020

COVID-19 Updates and Daily News

Featured jobs


Add my company
Health Unlimited

Health Unlimited is a global health consultancy and communications agency built by specialists with unmatched experience, perspective and expertise. For...

Latest intelligence

2020 - a year to remember or forget?
2020 and the Covid pandemic brought immense challenges, and the need for change felt like it happened overnight. What have we learned and what does the future of agency working...
Gilead Headquarters
The search for effective drug treatments for COVID-19
PME talks to Julian Cole, Senior Director, Medical Affairs at Gilead Sciences...
PME Jan cover
AstraZeneca’s focus on diagnosing and managing chronic kidney disease
People living with chronic kidney disease are in urgent need of new and improved approaches to diagnosis and care...